We can’t show the full text here under this license.
Reasons people stop using semaglutide or tirzepatide for weight loss in real-life treatment
Updated
Abstract
Essence
In routine obesity care, semaglutide or tirzepatide was most often stopped because of cost or insurance barriers.
Evidence
This cross-sectional electronic health record study reviewed a random sample of 288 adults without type 2 diabetes who discontinued semaglutide or tirzepatide within 1 year, with 47.6% stopping for cost or insurance reasons.
Caveat
The results come from a single health system and depend on documented discontinuation reasons in the medical record, which were unspecified for 11.1% of patients.
Simplified
Key numbers
137
Due to Cost or Insurance-Related Issues
Out of 288 patients who discontinued treatment
42
Due to Side Effects
Out of 288 patients who discontinued treatment
34
Due to Medication Shortages
Out of 288 patients who discontinued treatment
GLP-1 Therapies